CLL18
MOIRAI

Phase III

A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab
vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously
untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual
residual disease for adjustment of treatment duration to improve outcomes

2023-510294-34-00  

BGB-11417-303

III

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/​or Refractory Chronic Lymphocytic Leukemia/​Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

EU-CT-Nummer:  2024-517131-52